Tag: Clinical
Conclusions
Claudin expression patterns showed a strong correlation with histological type of OSCC; claudin expression was decreased in areas of invasion, and negative in poorly differentiated tumours. This pattern may be related to evolution and prognosis of these tumours, especially in the case of claudin 7, which seems to be associated with a poor prognosis in OSCC. (Source: Journal of Clinical Pathology)
Source: MedWorm: Oral Cancer
Tags: carcinoma, cases, cell, claudins, Clinical, different, histopathological, junction, Oral, parameters., patterns, relationship, squamous, Status, Study, tight, tissuemicroarraybased
Posted in Treatment | No Comments »
When combined with standard chemotherapy, an international Phase III trial has shown that the oral targeted treatment vandetanib improves progression-free survival for patients with advanced non-small cell lung cancer, as per research from The University of Texas MD Anderson Cancer Center. The findings, reported in the Lancet Oncology, mark the first clinical benefit of a small molecule targeted agent and standard chemotherapy in combination for lung cancer. The study was first presented at the 2009 Annual Meeting of the American Society of Clinical Oncology…….. (Source: Medicineworld.org: New Article Alert)
Source: MedWorm: Oral Cancer
Tags: benefit, Cancer, Clinical, lung, shows, Vandetanib
Posted in Treatment | No Comments »
Abbott data being presented includes two oral presentations on elotuzumab, an antibody designed to bind to the CS1 glycoprotein, a highly expressed cell surface protein in multiple myeloma. Four separate studies of linifanib (ABT-869), which is being studied as an inhibitor of the VEGFR and PDGFR kinase pathways, in advanced renal cell cancer (RCC), advanced solid tumors, advanced hepatocellular carcinoma (HCC) and non small cell lung cancer (NSCLC), also will be presented.06/04/2010 (Source: Kidney Cancer Association)
Source: MedWorm: Oral Cancer
Tags: Abbott, American, Annual, Cancer, Clinical, Data, Investigational, meeting, Oncology, Present, Several, Society, Treatments
Posted in Treatment | No Comments »
Preventive treatment for those at risk for bone loss may minimize adverse effects of anastrozole. Breast Cancer Research (Source: Medscape Today Headlines)
Source: MedWorm: Oral Cancer
Tags: AnastrozoleInduced, ARBI, Bone, Breast, Cancer, Clinical, Loss, Management, Oral, patients, Prospective, Results, Risedronate, Trial
Posted in Treatment | No Comments »
Marshall Edwards, Inc., (NASDAQ: MSHL). An abstract titled “A phase II study of oral phenoxodiol in castrate and non-castrate prostate cancer patients with associated cytokine changes” by Dr Kevin Kelly at the Yale School of Medicine Department of Medical Oncology, is now available at http://www.asco.org (abstract # 4661). The findings from this study in which safety and efficacy of phenoxodiol in both early (pre-metastatic) and late stage disease has been compared will be presented June 7, 2010 at the Annual Meeting of the American Society of Clinical Oncology (ASCO), Chicago, Illinois… (Source: Health News from Medical News Today)
Source: MedWorm: Oral Cancer
Tags: ASCO, Cancer, Clinical, Edwards, Marshall, Phase, Phenoxodiol, Presented, Prostate, Report, Study
Posted in Treatment | No Comments »
SAN DIEGO, CA (MARKET WIRE) Marshall Edwards, Inc., (NASDAQ: MSHL). An abstract titled “A phase II study of oral phenoxodiol in castrate and non-castrate prostate cancer patients with associated cytokine changes” by Dr Kevin Kelly at the Yale School of Medicine Department of Medical Oncology, is now available at www.asco.org (abstract # 4661). The findings from this study in which safety and efficacy of phenoxodiol in both early (pre-metastatic) and late stage disease has been compared will be presented June 7, 2010 at the Annual Meeting of the American Society of Clinical Oncology (ASCO), Chicago, Illinois. (Source: Market Wire – Pharmaceuticals and Biotech)
Source: MedWorm: Oral Cancer
Tags: ASCO, Cancer, Clinical, Edwards, Inc., Marshall, Phase, Phenoxodiol, Presented, Prostate, Report, Study
Posted in Treatment | No Comments »
CONCLUSION: The cytologic analysis was not useful for detecting epithelial dysplasia or malignant alterations. (Source: Clinics)
Source: MedWorm: Oral Cancer
Tags: Actinic, analysis, Clinical, cytopathological, fishermen's, histopathologic, lesions, lower
Posted in Treatment | No Comments »
Delcath Systems, Inc. (Nasdaq: DCTH), a medical technology company testing its proprietary treatment system for primary and metastatic cancers to the liver, announced that the American Society of Clinical Oncology (ASCO) has accepted an abstract for oral presentation of Delcath’s Phase III Trial Data comparing percutaneous hepatic perfusion with melphalan (PHP-mel) to the best alternative care for patients with hepatic metastases from ocular or cutaneous melanoma for ASCO’s 2010 Annual Meeting, to be held June 4-8, 2010 at McCormick Place in Chicago. James F… (Source: Health News from Medical News Today)
MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed – updated hourly from thousands of authoritative health and news sources.
Source: MedWorm: Oral Cancer
Tags: 2010, American, Annual, Chicago, Clinical, Data, Delcath's, During, meeting, Oncology, Phase, Presented, Society, Trial
Posted in Treatment | No Comments »
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) announced topline results from the company’s phase 2 clinical trial of SCV-07 for the prevention of severe oral mucositis (OM) (World Health Organization, WHO scale, grades 3 to 4) — a painful, debilitating, and costly toxicity caused by chemoradiotherapy regimens used to treat head and neck cancer. This proof of concept study was intended to provide an estimate of SCV-07’s treatment effect and guide further studies of SCV-07 in addressing this serious unmet medical need. Patients receiving the study’s higher dose (0… (Source: Health News from Medical News Today)
MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed – updated hourly from thousands of authoritative health and news sources.
Source: MedWorm: Oral Cancer
Tags: Announces, Clinical, Mucositis, Oral, Phase, Prevention, Results, SciClone, SCV07, Topline, Trial
Posted in Treatment | No Comments »
Portola Pharmaceuticals, Inc. announced that it has initiated its first in human Phase 1 trial in healthy volunteers of PRT062607, a novel, oral Syk-specific kinase inhibitor in development to treat chronic inflammatory diseases, including rheumatoid arthritis (RA), and certain cancers, including non-Hodgkin’s lymphoma and chronic lymphocytic leukemia. In preclinical in vivo models of RA, PRT062607 was shown to reduce inflammation in a dose-dependent manner… (Source: Health News from Medical News Today)
MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed – updated hourly from thousands of authoritative health and news sources.
Source: MedWorm: Oral Cancer
Tags: Announces, Chronic, Clinical, disease, Inflammatory, Inhibitor, Initiation, Oral, Pharmaceuticals, Phase, Portola, PRT062607, SykSpecific, Trial
Posted in Treatment | No Comments »
